Skip to main content

Table 1 Patient and disease characteristics and prior treatments

From: Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

Characteristics LD 5-FU (n = 7) HD 5-FU (n = 45) Total (n = 52)
Gender, M/F (%) 57/43 64/36 63.5/36.5
Median age, years [range] 66 [49–73] 61 [25–77] 61 [25–77]
Median KPS [range] 100 [80–100] 100 [60–100] 100 [60–100]
Median duration of disease, months [range] 1.4 [1–25] 1.5 [0–84] 1.5 [0–84]
Primary tumour site (%):    
   Colon 86 67 69
   Rectum 14 33 31
Previous adjuvant chemotherapy (%) 14 20 19
Number of involved organs (%) ≤ 2 100 93 94
Normal WBC at baseline (%) 100 96 96
Normal LDH at baseline (%) 57 49 50
Normal ALP at baseline (%) 29 36 35
EGFR status (%):a    
   0–≤10 43 42 42
   >10–≤20 14 13 14
   >20–≤35 29 13 15
   >35 14 31 29
  1. aPercentage of positive cells; LD = low-dose; HD = high-dose; KPS = Karnofsky Performance Status; WBC = white blood cell; LDH = lactate dehydrogenase; ALP = alkaline phosphatase; EGFR = epidermal growth factor receptor.